Observational studyJournal of neuro-oncology2016
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Observational study in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.The Cochrane database of systematic reviews · 2021Pooled it
- The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.BMC cancer · 2020Pooled it
- Management of elderly patients with glioblastoma-multiforme-a systematic review.The British journal of radiology · 2018Pooled it
- Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.Radiation oncology (London, England) · 2017Trial
- Risk factors for unintended discontinuation of tumor-specific treatment after tumor surgery in glioblastoma patients aged 70 or older.Brain & spine · 2025Article
- Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.Neuro-oncology practice · 2024Article
- Current chemotherapy strategies for adults with IDH-wildtype glioblastoma.Frontiers in oncology · 2024Review
- Newly Diagnosed Glioblastoma in Elderly Patients.Current oncology reports · 2022Review
- Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?Brain tumor research and treatment · 2022Review
- Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.Scientific reports · 2021Article
- Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus.Journal of neuro-oncology · 2018Article
- Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.Journal of neuro-oncology · 2018Article
- MicroRNA‑1288 promotes cell proliferation of human glioblastoma cells by repressing ubiquitin carboxyl‑terminal hydrolase CYLD expression.Molecular medicine reports · 2017Article
- Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume.Journal of neuro-oncology · 2017Article
- Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.Journal of neuro-oncology · 2017Article
- MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.American journal of cancer research · 2016Article
- On the value of microsurgical resection compared to biopsy in elderly glioblastoma patients: A retrospective multicenter analysis and scoring system proposal.Neuro-oncology advancesArticle
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0-3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8-13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6-14.6), and 9.3 months (95 % CI 8.1-10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5-22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.
Indexed as
Identifiers
26943851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.